[EN] AMINO BI- AND TRI-CARBOCYCLIC ALKANE BIS-ARYL SQUALENE SYNTHASE INHIBITORS<br/>[FR] AMINO-ALCANES BI- ET TRI-CARBOCYCLIQUES A SUBSTITUTION BIS-ARYLE UTILISES COMME INHIBITEURS DE SQUALENE SYNTHASE
申请人:RHONE-POULENC RORER PHARMACEUTICALS INC.
公开号:WO1995000146A1
公开(公告)日:1995-01-05
(EN) This invention relates to a class of novel amino bi- and tri-carbocyclic alkane compounds having bis-aryl substitution which exhibit squalene synthase inhibition properties. The bi- and tri-carbocyclic alkane ring contains an amino group and the ring is further linked or bridged to two mono- and/or bicyclic rings. Compounds of this invention reduce levels of serum cholesterol in the body without significantly reducing mevalonic metabolite synthesis. This invention relates also to pharmacological compositions and method of treatment for lowering serum cholesterol levels using the compounds of this invention.(FR) Cette invention concerne une classe de nouveaux composés amino-alcanes bi- et tri-carbocycliques ayant une substitution bis-aryle qui ont des propriétés d'inhibition de squalène synthase. Le cycle alcane bi- et tri-carbocyclique contient un groupe amine et ce cycle est également lié à deux noyaux mono- et/ou bicycliques. Les composés de cette invention diminuent les niveaux de cholestérol sérique dans le corps sans diminuer de façon significative la synthèse des métabolites mévaloniques. Cette invention concerne également des compositions pharmacologiques et une méthode de traitement abaissant le niveau de cholestérol sérique utilisant les composés de cette invention.
A concise and efficient synthesis of vildagliptin
作者:Michele Castaldi、Marco Baratella、Ivan G. Menegotto、Graziano Castaldi、Giovanni B. Giovenzana
DOI:10.1016/j.tetlet.2017.07.062
日期:2017.8
An original synthesis of vildagliptin ((S)-1-[2-(3-hydroxyadamantan-1-ylamino)acetyl]pyrrolidine-2-carbonitrile), a powerful DPP-4 inhibitor, was developed. Vildagliptin was assembled from 3-amino-1-adamantanol, glyoxylic acid and l-prolinamide in a 4-step reaction sequence with the isolation of only two intermediates. The procedure is competitive with existing protocols, leading to vildagliptin in